DocMorris accelerates Rx growth to 78% in Q3; EBITDA breakeven already achieved in Q3 and revenue and EBITDA forecast for 2026 raised again
DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris accelerates Rx growth to 78% in Q3; EBITDA breakeven already achieved in Q3 and revenue and EBITDA forecast for 2026 raised again 15-Oct-2026 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for